CEVEC has been granted a new CAP®Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach

  • New patent paves the way for further market expansion for CAP®Go expression platform
  • Patent strengthens CEVEC’s unique position in producing recombinant proteins with tailor-made glycosylation
  • Important milestone in establishing CAP®Go as the production standard for difficult-to-express recombinant glycoproteins

Cologne, Germany, November 14, 2017

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company has been granted a patent for its expression technology CAP®Go entitled, “O-glycan sialylated recombinant glycoproteins and cell lines for producing the same,” by the Australian Patent Office.